FY2027 EPS Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Raised by Analyst

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Equities researchers at Wedbush increased their FY2027 earnings estimates for SpringWorks Therapeutics in a research report issued on Wednesday, August 28th. Wedbush analyst D. Nierengarten now expects that the company will earn $3.56 per share for the year, up from their previous estimate of $3.41. Wedbush has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.34) per share.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.58. The company had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. During the same period last year, the company posted ($1.25) EPS. The business’s revenue for the quarter was up 59732900.0% on a year-over-year basis.

Separately, HC Wainwright reiterated a “buy” rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a research note on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $69.50.

SpringWorks Therapeutics Stock Performance

Shares of SWTX stock opened at $41.71 on Thursday. SpringWorks Therapeutics has a one year low of $18.00 and a one year high of $53.92. The company has a 50 day moving average price of $37.72 and a 200 day moving average price of $42.60. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -8.11 and a beta of 0.78.

Institutional Investors Weigh In On SpringWorks Therapeutics

Several institutional investors have recently bought and sold shares of the business. Quarry LP grew its stake in SpringWorks Therapeutics by 56.3% during the second quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after buying an additional 1,800 shares during the period. Algert Global LLC boosted its stake in shares of SpringWorks Therapeutics by 62.7% in the second quarter. Algert Global LLC now owns 34,989 shares of the company’s stock valued at $1,318,000 after purchasing an additional 13,489 shares during the period. Maverick Capital Ltd. boosted its stake in shares of SpringWorks Therapeutics by 36.3% in the second quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company’s stock valued at $97,962,000 after purchasing an additional 691,894 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in shares of SpringWorks Therapeutics by 16.9% in the second quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock valued at $28,581,000 after purchasing an additional 109,865 shares during the period. Finally, Duquesne Family Office LLC purchased a new position in shares of SpringWorks Therapeutics in the second quarter valued at $38,475,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.